Dyve Biosciences

Dyve creates novel therapeutics using proprietary science that leverages the skin as a portal for systemic delivery.

[Dyve Biosciences @DyveBio]

Dyve Biosciences is proud to announce FDA clearance to initiate phase 2 study of DYV-700 for treatment of acute #gout pain.
Full press release: https://t.co/KLO5r9OFEb

[Dyve Biosciences @DyveBio]

Dyve’s science has demonstrated the power to deliver up to 40% of the applied dose into the blood, which exceeds what is seen by many pills. #biotech

[Dyve Biosciences @DyveBio]

Thank you to @MassDevice for highlighting Dyve's press release announcing first patient enrollment in Phase 2 TARGETS Study for Acute Gout: https://t.co/Z7Y4X5Uh1o

#gout #biotech #clinicaltrials

[Dyve Biosciences @DyveBio]

Thank you @Machiz and @Nasdaq for featuring Dyve in their #NasdaqSpotlight series in New York City last week! You can view the full interview with CEO Ryan Beal on Dyve's website: https://t.co/2kjYnPvCDW

#biotech #healthcare

[Dyve Biosciences @DyveBio]

First subjects were enrolled in Dyve's Phase 2 TARGETS study this week! Thank you to all of our partners for making this achievement possible. It is an exciting milestone for our company! #gout #biotech

[Dyve Biosciences @DyveBio]

We had an exciting week in New York! Thank you to @IAmBiotech for hosting #BIOCEO20 as well as @Nasdaq for highlighting Dyve on #NasdaqSpotlight! #biotech

[Dyve Biosciences @DyveBio]

Thanks to @byndergroup for their continued partnership and the amazing work they've put into developing our website! https://t.co/70R8IENiT4

[Biotechnology Innovation Organization @IAmBiotech]

BIO is helping leaders fulfill that commitment by providing resources to help build a more inclusive and diverse workforce. Learn more at https://t.co/yzJvmznVct #rightmixmatters

[Dyve Biosciences @DyveBio]

@mikewill91 Thanks, Mike!

[Dyve Biosciences @DyveBio]

Dyve is thrilled to welcome longtime Pfizer Executive Chuck Harbert, Ph.D. to the company in the role of Chief Scientific Officer.
Full press release: https://t.co/58c6jPKyQQ
Learn more about Dyve: https://t.co/70R8IENiT4

[Dyve Biosciences @DyveBio]

Gout flares are characterized by the formation of sodium urate crystals in the joint space, causing intense pain typically lasting 48-96 hours.

[Dyve Biosciences @DyveBio]

@mikewill91 Thanks for the interest @mikewill91! You can get in touch with us through our contact page: https://t.co/1yc7RYFTKh and someone from our team will reach out to connect.

[Dyve Biosciences @DyveBio]

DYV-700 was recently approved for phase 2 trial for treatment of acute gout pain. Here's why we're excited.

[MassDevice @MassDevice]

.@DyveBio wins FDA nod for Phase 2 transdermal drug delivery trial https://t.co/nOaK6V0HF3

[Dyve Biosciences @DyveBio]

@mikewill91 Thank you, Mike!

[Dyve Biosciences @DyveBio]

@sclinical Thank you for your interest! We will share your contact info with the team and will reach out if it seems like a good fit.

[Dyve Biosciences @DyveBio]

Dyve Biosciences is proud to announce FDA clearance to initiate phase 2 study of DYV-700 for treatment of acute #gout pain.
Full press release: https://t.co/KLO5r9OFEb

[Dyve Biosciences @DyveBio]

@audieb70 Thanks Audra!

[Dyve Biosciences @DyveBio]

CEO Ryan Beal, MD chatted with @ModAesthetics about the latest research on Dyve's technology.

Check out the full article: https://t.co/ZnZ2l4gVMV

[Dermatology Times @DermTimesNow]

When should lasers be used to treat #melasma? Mildred López Piñeiro, M.D. provides her insight in our new column on energy devices. https://t.co/yHK8KEOGOo

[Dyve Biosciences @DyveBio]

Dyve's SAB member Smitha Reddy, MD with CEO Ryan Beal, MD before Dr. Reddy's poster presentation at #ACR19 in Atlanta.

For the complete poster, visit our publications page on our website:

https://t.co/aTgLRDCXjd